Asset Details
Do you wish to reserve the book?
Selection of Plasmodium falciparum cytochrome B mutants by putative PfNDH2 inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Selection of Plasmodium falciparum cytochrome B mutants by putative PfNDH2 inhibitors
Do you wish to request the book?
Selection of Plasmodium falciparum cytochrome B mutants by putative PfNDH2 inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Selection of Plasmodium falciparum cytochrome B mutants by putative PfNDH2 inhibitors
2018
Overview
Malaria control is threatened by a limited pipeline of effective pharmaceuticals against drug-resistant strains of Plasmodium falciparum. Components of the mitochondrial electron transport chain (ETC) are attractive targets for drug development, owing to exploitable differences between the parasite and human ETC. Disruption of ETC function interferes with metabolic processes including de novo pyrimidine synthesis, essential for nucleic acid replication. We investigated the effects of ETC inhibitor selection on two distinct P. falciparum clones, Dd2 and 106/1. Compounds CK-2-68 and RYL-552, substituted quinolones reported to block P. falciparum NADH dehydrogenase 2 (PfNDH2; a type II NADH:quinone oxidoreductase), unexpectedly selected mutations at the quinol oxidation (Qₒ) pocket of P. falciparum cytochrome B (PfCytB). Selection experiments with atovaquone (ATQ) on 106/1 parasites yielded highly resistant PfCytB Y268S mutants seen in clinical infections that fail ATQ-proguanil treatment. In contrast, ATQ pressure on Dd2 yielded moderately resistant parasites carrying a PfCytB M133I or K272R mutation. Strikingly, all ATQ-selected mutants demonstrated little change or slight increase of sensitivity to CK-2-68 or RYL-552. Molecular docking studies demonstrated binding of all three ETC inhibitors to the Qₒ pocket of PfCytB, where Y268 forms strong van der Waals interactions with the hydroxynaphthoquinone ring of ATQ but not the quinolone ring of CK-2-68 or RYL-552. Our results suggest that combinations of suitable ETC inhibitors may be able to subvert or delay the development of P. falciparum drug resistance.
Publisher
National Academy of Sciences
Subject
/ Drug Resistance - drug effects
/ Electron Transport Chain Complex Proteins - genetics
/ Malaria
/ Malaria, Falciparum - drug therapy
/ Malaria, Falciparum - genetics
/ Malaria, Falciparum - parasitology
/ Molecular Docking Simulation - methods
/ Mutation
/ NADH
/ NADH Dehydrogenase - antagonists & inhibitors
/ Nicotinamide adenine dinucleotide
/ Plasmodium falciparum - drug effects
